Publications by authors named "Jose Estevam"

Claim this Profile
A
Advancing Point-of-Care Applications with Droplet Microfluidics: From Single-Cell to Multicellular Analysis.
Christina Sharkey, Rachel White, Michael Finocchiaro, Judene Thomas, Jose Estevam

Annu Rev Biomed Eng· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials.
Bruno Paiva, Irene Manrique, Meletios A Dimopoulos, Francesca Gay, Chang-Ki Min, Jose Estevam

Blood· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2021 White Paper on Recent Issues in Bioanalysis: ISR for Biomarkers, Liquid Biopsies, Spectral Cytometry, Inhalation/Oral & Multispecific Biotherapeutics, Accuracy/LLOQ for Flow Cytometry ( - Recommendations on Biomarkers/CDx Assays Development & Validation, Cytometry Validation & Innovation, Biotherapeutics PK LBA Regulated Bioanalysis, Critical Reagents & Positive Controls Generation).
Sarah Hersey, Steve Keller, Joel Mathews, Lindsay King, Abbas Bandukwala, Jose Estevam

Bioanalysis· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2020 White Paper on Recent Issues in Bioanalysis: BAV Guidance, CLSI H62, Biotherapeutics Stability, Parallelism Testing, CyTOF and Regulatory Feedback ( - Recommendations on Biotherapeutics Stability, PK LBA Regulated Bioanalysis, Biomarkers Assays, Cytometry Validation & Innovation - Regulatory Agencies' Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene & Cell Therapy and Vaccine).
Susan Spitz, Yan Zhang, Sally Fischer, Kristina McGuire, Ulrike Sommer, Jose Estevam

Bioanalysis· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and validation of a high-parameter mass cytometry workflow to decipher immunomodulatory changes in celiac disease.
Jose Estevam, Peter Krutzik, Jason Vander Tuig, William J McAuliffe, Glennda Smithson

Cytometry B Clin Cytom· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects.
Eric R Fedyk, Lin Zhao, Annelize Koch, Glennda Smithson, Jose Estevam

Br J Clin Pharmacol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyt-Geist: Current and Future Challenges in Cytometry: Reports of the CYTO 2019 Conference Workshops.
Kamila Czechowska, Joanne Lannigan, Nima Aghaeepour, Jessica B Back, Julfa Begum, Jose Estevam

Cytometry A· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma.
Jesús F San-Miguel, Maria-Asunción Echeveste Gutierrez, Ivan Špicka, María-Victoria Mateos, Kevin Song, Jose Estevam

Haematologica· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.
Paul G Richardson, Craig C Hofmeister, Cara A Rosenbaum, Myo Htut, David H Vesole, Jose Estevam

Br J Haematol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo.
Melissa Gallery, Julie Zhang, Daniel P Bradley, Pamela Brauer, Donna Cvet, Jose Estevam

PLoS One· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab.
Tim Wyant, Jose Estevam, Lili Yang, Maria Rosario

Cytometry B Clin Cytom· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Shaji K Kumar, Jesus G Berdeja, Ruben Niesvizky, Sagar Lonial, Jacob P Laubach, Jose Estevam

Lancet Oncol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
Shaji Kumar, Ian Flinn, Paul G Richardson, Parameswaran Hari, Natalie Callander, Jose Estevam

Blood· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of a flow cytometry based G(2)M delay cell cycle assay for use in evaluating the pharmacodynamic response to Aurora A inhibition.
Jose Estevam, Hadi Danaee, Ray Liu, Jeffrey Ecsedy, William L Trepicchio

J Immunol Methods· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis